Traditional Chinese medicine composition for treating metabolism-related fatty liver diseases as well as preparation method and application of traditional Chinese medicine composition

Abstract

The invention discloses a traditional Chinese medicine composition for treating metabolism-related fatty liver diseases. The traditional Chinese medicine composition comprises 10-20 g of fructus aurantii stir-fried with bran, 10-20 g of wine-processed radix scutellariae, 30-60 g of sedum sarmentosum, 10-20 g of codonopsis pilosula, 15-30 g of astragalus membranaceus, 10-20 g of bran-fried rhizoma atractylodis macrocephalae, 10-20 g of poria cocos, 6-12 g of vinegar-processed radix bupleuri, 10-20 g of parched white peony root, 10-20 g of vinegar-processed rhizoma cyperi, 10-20 g of pericarpium citri reticulatae, 10-20 g of vinegar-processed pericarpium citri reticulatae viride, 10-20 g of rhizoma pinellinae praeparata, 10-20 g of lotus leaf (large), 10-20 g of rhizoma alismatis, 10-20 g of scorched hawthorn fruit, a syndrome differentiation and treatment method is adopted, an optimal formula is screened out through a large number of experiments, treatment is conducted from the spleen, phlegm reducing and dampness clearing are adopted as a major method, the weight reducing effect is achieved, MAFLD is relieved, and it is clinically proved that the traditional Chinese medicine composition has a remarkable treatment effect on metabolism-related fatty liver diseases.

Description

technical field [0001] The invention relates to a traditional Chinese medicine composition, in particular to a traditional Chinese medicinal composition for treating metabolism-related fatty liver disease and a preparation method thereof, belonging to the technical field of medicine. Background technique [0002] Metabolic-associated fatty liver disease (MAFLD) is a common clinical disease and frequently-occurring disease. Traditional Chinese medicine corresponds to "liver addiction" and "liver stagnation". In recent years, the incidence rate in my country has increased year by year, and the global prevalence rate As high as 25%, it seriously endangers human health and causes huge economic burden to the society. So far, there is no drug approved for the treatment of MAFLD in my country, the United States and the European Union, so it is urgent to find an effective treatment method. [0003] The recent consensus goals of MAFLD therapy are weight loss, reduction of hepatic fat...

AI Technical Summary

Problems solved by technology

At present, there are limited drugs for weight loss clinically, and they are often accompanied by side effects such as strong gastrointestinal reactions. However, in the long clinical history of tr